The once-daily oral drug Rasonque (daraxonrasib), developed by Revolution Medicines, works by blocking activated RAS proteins – key drivers of tumour growth in most patients with pancreatic adenocarcinoma, the most common and most aggressive form of pancreatic cancer.
The positive opinion from the CHMP, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use, is based on results from a randomised, multicentre study involving 500 patients with metastatic pancreatic cancer whose disease had progressed after previous systemic treatment.
BREAKING